Investors
Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets. Novo Holdings is recognised as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. For more information visit novoholdings.dk
Pureos Partners is a Swiss venture capital firm and the investment adviser of Pureos Bioventures. It invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats. The fund’s portfolio companies are built on scientific excellence to develop therapies across a broad indication spectrum including oncology, immunology, ophthalmology, rare diseases, and neuroscience. Pureos has built a team with in-depth investment, operating and clinical expertise, that strives to impact patients’ lives by advancing innovative treatments for devastating diseases. For more information visit pureosbio.com
The Lichtsteiner Foundation is a charitable, independent Swiss foundation headquartered in Bern, established in 2009 by Richard Lichtsteiner — a pioneering entrepreneur and co-founder of Interdiscount, Switzerland's largest electronics discounter. Its mission is to promote innovations in healthcare in order to improve people's health worldwide, with a focus on areas such as medtech, life science, biotech, mental health, and public health. The foundation supports six to ten early-stage Swiss startups each year, with a focus on highly innovative solutions that tackle common health problems or niche medical markets, led by founders with the drive and competence to bring their technology to market. For more information visit lichtsteinerfoundation.org